4/A: Unicycive Executive Receives RSU Grant

Pramod Gupta, EVP of Pharmaceuticals and BD at Unicycive Therapeutics, was granted 169,500 restricted stock units.

Summary

• Pramod Gupta, EVP of Pharmaceuticals and Business Development at Unicycive Therapeutics, received a grant of 169,500 restricted stock units (RSUs).
• The grant is payable solely in common stock of the issuer.
• Vesting schedule includes an immediate grant of 23,542 shares, with the remaining 145,958 shares vesting monthly over 31 months starting June 1, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation that carries no significant signal regarding company performance.

Positives

• Alignment of executive interests with long-term shareholder value through equity-based compensation.
• Retention mechanism established via a 31-month vesting schedule for the majority of the grant.

Negatives

• Potential for future shareholder dilution upon the conversion of RSUs into common stock.

Risks

• Continued service requirement for vesting creates dependency on executive retention.
• Market volatility affecting the ultimate value of the equity compensation.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on executive compensation structure.

Management Comments

• The RSU award is subject to the Reporting Person's continued service with the Issuer.

Industry Context

StockSavvy.ai notes that equity-based compensation remains a standard practice in the biotechnology sector to preserve cash while incentivizing key leadership roles.

Comparison to Industry Standards

• The use of RSU grants with multi-year vesting schedules is consistent with standard executive compensation practices in small-cap biotech firms.
• The structure aligns with typical retention strategies used by peers to mitigate turnover in high-stakes R&D environments.

Stakeholder Impact

• Shareholders may experience minor dilution as RSUs vest and convert to common stock.

Next Steps

• Monthly vesting of 4,708 shares beginning June 1, 2026.

Key Dates

Keywords

Unicycive Therapeutics, UNCY, Form 4, Insider Transaction, Restricted Stock Units, Executive Compensation